Breaking News Instant updates and real-time market news.

JPM

JPMorgan

$109.78

1.14 (1.05%)

, AKZOY

AkzoNobel

$0.00

(0.00%)

13:24
05/25/19
05/25
13:24
05/25/19
13:24

Microsoft, JPMorgan among dividend champions, Barron's says

Among the companies that paid out the most in first quarter dividends, most have high yields as well, Lawrence Strauss writes in this week's edition of Barron's. Those include BHP Group (BHP), Novartis (NVS), Roche (RHHBY), Royal Dutch Shell (RDS.A), AT&T (T), Siemens (SIEGY), Commonwealth Bank of Australia (CMWAY), Microsoft (MSFT), Exxon Mobil (XOM), Akzo Nobel (AKZOY), and JPMorgan (JPM). Reference Link

JPM

JPMorgan

$109.78

1.14 (1.05%)

AKZOY

AkzoNobel

$0.00

(0.00%)

XOM

Exxon Mobil

$74.12

0.33 (0.45%)

MSFT

Microsoft

$126.23

0.04 (0.03%)

CMWAY

Commonwealth Bank of Australia

$0.00

(0.00%)

SIEGY

Siemens

$0.00

(0.00%)

T

AT&T

$32.29

0.15 (0.47%)

RDS.A

Royal Dutch Shell

$63.29

0.84 (1.35%)

RHHBY

Roche

$0.00

(0.00%)

NVS

Novartis

$87.49

3.03 (3.59%)

BHP

BHP Group

$52.47

1.18 (2.30%)

  • 28

    May

  • 29

    May

  • 29

    May

  • 31

    May

  • 03

    Jun

  • 03

    Jun

  • 03

    Jun

  • 05

    Jun

  • 08

    Jun

  • 10

    Jun

  • 10

    Jun

  • 11

    Jun

  • 11

    Jun

  • 12

    Jun

  • 20

    Jun

  • 23

    Jun

  • 16

    Jul

  • 24

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 02

    Sep

  • 04

    Nov

JPM JPMorgan
$109.78

1.14 (1.05%)

03/19/19
KEYB
03/19/19
DOWNGRADE
KEYB
Sector Weight
Worldpay downgraded to Sector Weight after Fiserv deal at KeyBanc
As previously reported, KeyBanc analyst Josh Beck downgraded Worldpay (WP) to Sector Weight from Overweight after the company and FIS (FIS) announced a deal, quickly adding another mega-deal in the wake of Fiserv (FISV)-First Data (FDC) and Global Payments (GPN)-Heartland Payment Systems. The analyst thinks this transaction is likely to expand the M&A discussion around Global Payments, TSYS (TSS), EVO Payments (EVOP), and i3 Verticals (IIIV) and sees paths to accretion should management teams further endorse a scale strategy. Future processing competition could increase among Global Payments, TSYS, First Data, and JPMorgan (JPM), but it remains too early to gauge, he contends.
02/28/19
BMOC
02/28/19
NO CHANGE
Target $116
BMOC
Market Perform
JPMorgan price target lowered to $116 from $123 at BMO Capital
BMO Capital analyst James Fotheringham lowered his price target on JPMorgan to $116 and kept his Market Perform rating, citing the company's Investor Day presentation that lowered expectations for net interest income as well as performance of its corporate & investment bank and wealth management segments. The analyst believes that other large-cap banks, fin-tech companies, and specialty lenders offer greater opportunity, even though his price target still implies a 13% return for JPMorgan stock.
03/06/19
03/06/19
NO CHANGE

JPMorgan files $130.14M mixed securities shelf
03/25/19
JEFF
03/25/19
NO CHANGE
JEFF
Jefferies downgrades Financials to Underweight on 'shocking' Fed meeting
Jefferies analyst Steven DeSanctis is "very surprised" by last week's Federal Reserve's decision taking rate hikes completely off table in 2019. The "shocking" Fed meeting means lower rates for longer, which is not good for Financials, DeSanctis tells investors in a research note. A "lack of catalysts and weaker earnings growth" going forward for the entire sector, not just banks, means an Underweight rating on the space makes sense, says the analyst. As such, he downgraded his rating on the Financial sector to Underweight from Market Weight. Publicly traded companies in the space include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
AKZOY AkzoNobel
$0.00

(0.00%)

12/07/18
JEFF
12/07/18
UPGRADE
JEFF
Buy
AkzoNobel upgraded to Buy from Hold at Jefferies
Jefferies analyst Laurence Alexander upgraded AkzoNobel to Buy and raised his price target for the shares to EUR 86 from EUR 84. The company's balance sheet, restructuring efforts and easing raw material costs offset any industrial market slowdown in the second half of 2019 or 2020,Alexander tells investors in a research note.
04/08/19
ABNA
04/08/19
DOWNGRADE
ABNA
Hold
AkzoNobel downgraded to Hold from Buy at ABN Amro
10/26/18
LEHM
10/26/18
UPGRADE
LEHM
Overweight
AkzoNobel upgraded to Overweight from Equal Weight at Barclays
10/10/18
MSCO
10/10/18
NO CHANGE
Target $102
MSCO
Equal Weight
Morgan Stanley cuts PPG estimates, but says Trian makes story 'more interesting'
After PPG (PPG) pre-announced Q3 and Q4 results that came in lower than Morgan Stanley's below-consensus forecast, analyst Vincent Andrews lowered his 2019 EPS estimate to $6.12 from $6.92 and said it would be below $6 without the benefit of $1.2B in assumed share repurchases during 2019. However, Trian's disclosure that it has built a 7M share stake "certainly makes the PPG story more interesting," given last year's failed approach of AkzoNobel (AKZOY) and the activist involvement at peers Akzo and RPM (RPM), Andrews tells investors. While he doesn't know what intentions Trian has in mind, his initial assessment is that Trian's focus will be on improving execution, most likely through a substantial cost restructuring program. Andrews, who added that "if nothing else comes out of all of this, we hope that PPG will begin to give annual earnings guidance," keeps an Equal Weight rating and $102 price target on PPG shares.
XOM Exxon Mobil
$74.12

0.33 (0.45%)

05/13/19
HSBC
05/13/19
DOWNGRADE
HSBC
Hold
Exxon Mobil downgraded to Hold from Buy at HSBC
04/08/19
TUDR
04/08/19
INITIATION
TUDR
Hold
Exxon Mobil initiated with a Hold at Tudor Pickering
05/13/19
HSBC
05/13/19
UPGRADE
HSBC
Buy
Royal Dutch Shell upgraded to Buy from Hold at HSBC
HSBC analyst Gordon Gray upgraded Royal Dutch Shell (RDS.A) to Buy from Hold. The analyst believes the global integrated oil sector is attractive following the recent selloff in the shares. With free cash break-evens in the low-$50s per barrel oil price, the majors are positioned for a period of sustained excess free cash flow and strong cash distributions, Gray tells investors in a research note. Deutsche Bank this morning also upgraded Royal Dutch Shell to Buy. Gray coupled his upgrade with a downgrade of Exxon Mobil (XOM) to Hold from Buy. He says Exxon's cash generation has been relatively weak.
05/15/19
GSCO
05/15/19
UPGRADE
Target $144
GSCO
Conviction Buy
Chevron upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman Sachs analyst Neil Mehta reinstated a rating on Chevron (CVX) at Buy and added the stock to the firm's Americas Conviction List, stating that Chevron's cash flow profile has positively inflected with the production contribution and capital spending roll-off from the startup of both the Gorgon and Wheatstone LNG projects. Chevron is demonstrating capital discipline, as demonstrated by its decision not to make a counterproposal to Occidental Petroleum's (OXY) offer for Anadarko (APC), and it has a lower capital spending growth rate and a higher production growth rate through 2023 than its closest peer, Exxon (XOM), said Mehta. The analyst has a $144 price target on Chevron shares.
MSFT Microsoft
$126.23

0.04 (0.03%)

05/22/19
FANA
05/22/19
NO CHANGE
Target $47
FANA
Strong Buy
Meetings with Pluralsight highlight GitPrime opportunity, says First Analysis
First Analysis analyst Corey Greendale kept his Strong Buy rating and $47 price target on Pluralsight (PS) after meeting with its management, saying the discussion highlighted opportunities around the "market expansion potential" from its GitPrime acquisition. The analyst believes that the company can generate strong free cash flow and produce organic revenue growth of over 30% as it continues to improve its sales and marketing efficiency. Greendale adds that Pluralsight managment also highlighted the "efficiency potential" of its Microsoft (MSFT) partnership.
05/22/19
OPCO
05/22/19
NO CHANGE
Target $145
OPCO
Outperform
Microsoft restructured itself around intelligent edge cloud, says Oppenheimer
After attending the Microsoft Build Developer Conference, Oppenheimer analyst Timothy Horan notes it became obvious that the company has totally restructured itself around the intelligent edge cloud. Microsoft sees Azure as a base layer that customers use to run their applications on top of but also as a building block for its services up the software "stack" through dozens of new PaaS and SaaS offerings, he contends. The analyst adds that by running on Azure, Microsoft applications become cheaper to operate, easier to innovate, and integrate the services. He reiterates an Outperform rating and $145 price target on the shares.
05/20/19
CHLM
05/20/19
DOWNGRADE
Target $35
CHLM
Hold
Cray downgraded to Hold from Buy at Craig-Hallum
Craig-Hallum analyst Chad Bennett downgraded Cray (CRAY) to Hold from Buy and lowered his price target on the shares to $35 from $36 after HP Enterprise (HPE) announced that it has entered into an agreement to purchase the company for $35.00 per share in cash, totaling $1.3B net of cash. The analyst believes the possibility of another buyer coming in over the top is fairly low, but notes that the price is "too low" based on the opportunities Cray has in front of it over the next few years. Furthermore, Bennett believes there would be a number of interested parties in Cray including Microsoft (MSFT), Dell (DELL), Intel (INTC), Alphabet (GOOG), Amazon (AMZN), and potentially IBM (IBM).
05/20/19
UBSW
05/20/19
NO CHANGE
Target $150
UBSW
Buy
Microsoft's Azure adoption proceeding well, says UBS
UBS analyst Jennifer Lowe kept her Buy rating and $150 price target on Microsoft after meeting with its Investor Relations executives last week, saying the discussions affirmed her view that adoption of the company's Azure is going well. The analyst expects Microsoft's margins to "work higher", adding that she is also positive on the company's growth prospects around Office 365 and cloud gaming. Lowe expects Microsoft to hold its current enterpise value to free cash flow multiple amid underlying growth in spite of the company investing more in its growth initiatives.
CMWAY Commonwealth Bank of Australia
$0.00

(0.00%)

09/10/18
SBSH
09/10/18
UPGRADE
SBSH
Neutral
Commonwealth Bank of Australia upgraded to Neutral from Sell at Citi
11/26/18
DBAB
11/26/18
DOWNGRADE
DBAB
Sell
Commonwealth Bank of Australia downgraded to Sell from Hold at Deutsche Bank
Deutsche Bank analyst Matthew Wilson downgraded Commonwealth Bank of Australia to Sell and lowered his price target for the shares to A$60 from A$75. The Australian banking sector confronts a "raft of real challenges and uncertainty," Wilson tells investors in a research note.
SIEGY Siemens
$0.00

(0.00%)

01/15/19
RBCM
01/15/19
INITIATION
RBCM
Sector Perform
Siemens initiated with a Sector Perform at RBC Capital
02/26/19
02/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Exact Sciences (EXAS) upgraded to Buy from Neutral at Goldman Sachs by analyst Patrick Donnelly, who said the current momentum of the Cologuard commercial ramp provides "strong basis" for the company's premium valuation while the combination of positive Cologuard catalysts and new product roll-outs provide upside to current levels, even after the stock's 75% rally since the beginning of 2018. Exact Sciences is a "must-own growth stock" given the "clean runway forward that is largely in its control with potential for discovery value in the pipeline outside of Cologuard," the analyst said. 2. Siemens (SIEGY) upgraded to Overweight from Neutral at JPMorgan by analyst Andreas Willi, who sees a relative valuation opportunity after the stock's 27% underperformance over the past two years. He believes investor sentiment can improve "after a period where the story has drifted." 3. Kadmon (KDMN) upgraded to Buy from Neutral at Citi by analyst Robyn Karnauskas, who assigned a 50% probability to KD-025 in chronic graft versus host disease with an unadjusted ~$900M market opportunity. However, upside to the stock will depend on quality of the data likely, Karnauskas said. 4. EverQuote (EVER) upgraded to Buy following Q4 beat at BofA/Merrill by analyst Mat Schindler, who said user growth has re-accelerated, supporting evidence of a turnaround, and thinks estimates are conservative and views the risk/reward as attractive. 5. Ally Financial (ALLY) upgraded to Buy from Hold at Sandler O'Neill by analyst Christopher Donat, who said he believes Ally's near-prime auto finance book is "meaningfully less risky" than Santander Consumer's (SC) book or the unsecured credit cards of Discover (DFS) and Capital One (COF), yet all four stocks trade at similar multiples. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/26/19
JPMS
02/26/19
UPGRADE
JPMS
Overweight
Siemens upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Andreas Willi upgraded Siemens to Overweight and raised his price target for the shares to EUR 118 from EUR 115. The analyst sees a relative valuation opportunity after the stock's 27% underperformance over the past two years. He believes investor sentiment can improve "after a period where the story has drifted." Siemens needs to adjust its Vision 2020+ strategy at the May meeting and reassure investors and provide substantiation of what will change, Willi tells investors in a research note.
05/21/19
FBCO
05/21/19
UPGRADE
FBCO
Outperform
Siemens upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Andre Kukhnin upgraded Siemens to Outperform from Neutral and raised his price target for the shares to EUR 143 from EUR 115.
T AT&T
$32.29

0.15 (0.47%)

05/03/19
NRCS
05/03/19
UPGRADE
Target $70
NRCS
Buy
Northcoast upgrades Generac to Buy as emerging play on 5G growth
As previously reported, Northcoast analyst Tom Hayes upgraded Generac to Buy from Neutral as he sees significant benefits from its increased closing rates for home standby units and the backup power needs associated with 5G growth. Spending for the infrastructure for 5G is expected to ramp to $26B in 2022 and Generac has established relationships with Verizon (VZ), AT&T (T) and T-Mobile (TMUS), noted Hayes, who believes the company is likely used by the major carriers in a significant percentage of all their back-up power needs. He set a $70 price target on Generac shares.
05/09/19
SBSH
05/09/19
UPGRADE
SBSH
Neutral
CenturyLink upgraded to Neutral on cash flow, cost cutting at Citi
As previously reported, Citi analyst Michael Rollins upgraded CenturyLink (CTL) to Neutral from Sell. While he said the company reported "another mixed quarter" and he thinks the pace of revenue decline should continue to depress the multiple, the company's "aggressive" cost cutting, cash flow and dividend yield should provide downside support, Rollins tells investors. He remains cautious on whether CenturyLink can create value by separating its consumer business, he added. Rollins recommends that investors seeking dividends in Telco buy AT&T (T) and Verizon (VZ) instead.
04/17/19
GSCO
04/17/19
NO CHANGE
GSCO
Sprint, T-Mobile headlines positive for Dish, Intelsat, says Goldman Sachs
Goldman Sachs analyst Brett Feldman, while taking no view on the outcome of the proposed merger between Sprint (S) and T-Mobile (TMUS), laid out his thoughts for other industry participants following the Wall Street Journal's report that the Department of Justice is unlikely to approve the deal as currently structured. The analyst believes investors will initially see the headlines as negative for the other major wireless carriers, namely AT&T (T) and Verizon (VZ), since they "create uncertainty over long-term industry structure." Further, investors will initially see these headlines as a slight positive for tower operators American Tower (AMT), Crown Castle (CCI) and SBA Communications (SBAC) as they "imply less risk of material cell site decommissioning," Feldman told investors earlier in a research note. The analyst also thinks investors will view the Journal's report as positive for owners of excess spectrum such as Dish (DISH) and Intelsat (I) and a slight positive for cable operators like Altice USA (ATUS), Charter (CHTR) and Comcast (CMCSA).
05/15/19
JPMS
05/15/19
NO CHANGE
Target $67
JPMS
Neutral
Amdocs price target lowered to $67 from $70 at JPMorgan
JPMorgan analyst Jackson Ader lowered his price target for Amdocs (DOX) to $67 from $70 saying that while the company's fiscal Q2 results were better than expected, the commentary on AT&T (T) is the main takeaway. AT&T revenue is off to a worse start for the first half than the company had expected as the focus on cost cutting and debt reduction within AT&T continues, Ader tells investors in a research note. The analyst does not see "this AT&T headwind going anywhere" and he keeps a Neutral rating on Amdocs.
RDS.A Royal Dutch Shell
$63.29

0.84 (1.35%)

05/09/19
MSCO
05/09/19
UPGRADE
MSCO
Equal Weight
Shell upgraded to Equal Weight ahead of expected dividend hike at Morgan Stanley
As previously reported, Morgan Stanley analyst Martijn Rats upgraded Royal Dutch Shell to Equal Weight from Underweight, stating that he expects Shell to extend its guidance for capex and free cash flow beyond the current planned period to 2021 at its investor day on June 4. Additionally, he thinks Shell will announce a dividend increase after an "unprecedented" period of five years with a flat dividend. His base case assumption is that management will choose a 2c, or 4%, dividend increase and will probably also make the case that free cash flow is available to sustain this distribution. Rats has a price target of 2,490p on Shell shares.
05/13/19
DBAB
05/13/19
UPGRADE
DBAB
Buy
Royal Dutch Shell upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded Royal Dutch Shell to Buy from Hold with a price target of 2700 pence.
05/13/19
05/13/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Royal Dutch Shell (RDS.A, RDS.B) upgraded to Buy from Hold at Deutsche Bank and HSBC. 2. KB Home (KBH) upgraded to Overweight from Equal Weight at Barclays with analyst Matthew Bouley saying his firm's spring agent survey confirmed that housing fundamentals have improved and stabilized. 3. Becton Dickinson (BDX) upgraded to Overweight from Equal Weight at Barclays with analyst Kristen Stewart saying the pullback in the shares since the FDA update on drug-coated balloons on March 15, coupled with the resetting of expectations following the company's Q2 results, provides an opportunity for investors. 4. Merck (MRK) upgraded to Overweight from Neutral at Atlantic Equities. 5. Bausch Health (BHC) upgraded to Neutral from Underweight at JPMorgan with analyst Chris Schott saying while a number of challenges remain in the story given the company's high leverage and controversial Xifaxan loss of exclusivity, its EBITDA is "clearly stabilizing and should begin to grow from here." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
RHHBY Roche
$0.00

(0.00%)

05/23/19
RBCM
05/23/19
NO CHANGE
Target $143
RBCM
Outperform
RBC sees 'interesting parallels' between Intercept and Roche-acquired InterMune
RBC Capital analyst Brian Abrahams said in a new note to investors that he sees "a number of interesting parallels" between Intercept (ICPT) and InterMune, which he notes was acquired by Roche (RHHBY) for $8.3B in 2014. While he admits that "it is not a perfect apples-to-apples comparison," he highlights that both companies' lead drugs had tolerability questions and finite exclusivity periods and that competitive risks have been "overly hyped" for Intercept's obeticholic acid and InterMune's Esbriet. The analyst, who contends that the similarities "further highlight the significant valuation disconnect" for Intercept, keeps an Outperform rating and $143 price target on the shares.
04/17/19
WELS
04/17/19
NO CHANGE
WELS
Outperform
Ionis pullback on Roche update a buying opportunity, says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterated his Outperform rating on Ionis Pharmaceuticals (IONS) following an update today from partner Roche (RHHBY) on its HTT-ASO program for Huntington's disease, stating that he believes the update continues to support potential for accelerated approval filing pending efficacy data that should be updated by year end. When asked during its earnings call about the specific filing strategy of using phase 1 OLE data in comparison to the natural history data, Roche made no comment beyond reiterating that the company will get data, share data with regulators, and work on the fastest way to bring the therapy to patients, said Birchenough. The analyst, who recommends buying Ionis on weakness, added that Roche noted that the company has had initial promising discussion with regulators.
05/09/19
LEHM
05/09/19
NO CHANGE
Target $245
LEHM
Equal Weight
Barclays cuts Biogen target to $245 on reduced Spinraza estimates
Barclays analyst Geoff Meacham lowered his price target for Biogen (BIIB) to $245 from $250 citing growing uncertainty in spinal muscular atrophy. Concerns over Spinraza in spinal muscular atrophy have intensified with the impending launch of Novartis' (NVS) gene therapy Zolgensma and Roche (RHHBY)/PTC's (PTCT) oral risdiplam, Meacham tells investors in a research note. The analyst says his feedback from key opinion leaders was "direct and unequivocal," with the leaders predicting "robust uptake" of both Zolgensma and risdiplam given signs of improved efficacy. This was at the expense of Spinraza driven by the clinical burden of intrathecal injections, says Meacham. On the basis of this feedback, he lowered his longer-term Spinraza outlook by ~$150M per year. The analyst now forecasts sales of $2.0B in 2019, declining to $1.7B in 2023. He keeps an Equal Weight rating on Biogen.
04/22/19
BMOC
04/22/19
NO CHANGE
Target $96
BMOC
Outperform
Ionis Pharmaceuticals price target raised to $96 from $82 at BMO Capital
BMO Capital analyst Do Kim raised his price target on Ionis Pharmaceuticals (IONS) to $96 and kept his outperform rating after including the risk-adjusted royalties for HTT-Rx in his model as part of the update on its partnership with Roche (RHHBY) disclosed last month. The analyst notes that the stock price has started to reflect the company's Huntington's disease opportunity based on the "potential for an accelerated path with Phase 2 data" and believes that his HTT-Rx projections could prove to be "conservative".
NVS Novartis
$87.49

3.03 (3.59%)

05/24/19
FBCO
05/24/19
NO CHANGE
FBCO
Underperform
Zolgensma label breadth on higher end of expectations, says Credit Suisse
Credit Suisse analyst Evan Seigerman noted that the FDA announced approval for Novartis' (NVS) Zolgensma for the treatment of Spinal Muscular Atrophy, or SMA, in patients with bi-allelic mutations in the SMN1 gene under 2 years of age. The current wholesale acquisition cost for Biogen's (BIIB) Spinraza equates to a per-year treatment cost of $500,000 for the first year loading phase and $250,000-$375,000 per year for maintenance thereafter, which compares to a WAC of $2.125M for Zolgensma, which is administered just once, noted Seigerman. While investors generally expected Zolgensma would be approved, the breadth of the label was on the higher end of expectations, Seigerman tells investors. The pricing and label support his below consensus view of Spinraza, as he continues to expect that Zolgensma will become the preferred first option for infant-onset type 1 SMA, said the analyst, who reiterates his $198 price target and Underperform rating on Biogen shares.
05/20/19
RBCM
05/20/19
NO CHANGE
RBCM
RBC says posting hints at Zolgensma label potentially positive for PTC, Biogen
RBC Capital analyst Brian Abrahams noted a new posting on ClinicalTrials.gov that he said "looks like" an expanded access program for Zolgensma that he believes could possibly offer some hints as to the potential label under discussion with the FDA. The most interesting parts are the inclusion criteria, which he thinks could "represent a middle ground" in terms of the breadth of label Novartis (NVS) could obtain for the drug. If the posting is predictive of Zolgensma's initial label, he said he would see it as an incremental positive for Biogen (BIIB), as it would potentially reduce the worst-case scenario of Zolgensma being approved with no age or weight restrictions. It would also be an incremental positive for PTC Therapeutics (PTCT), which Abrahams noted is looking to enter the space.
05/17/19
FBCO
05/17/19
NO CHANGE
Target $68
FBCO
Outperform
Alcon off to 'solid start' post-Novartis spin, says Credit Suisse
Credit Suisse analyst Matt Miksic reiterated an Outperform rating on Alcon (ALC) and raised his price target to $68 from $66 following the company's quarterly results, saying Alcon is off to a "solid start" following the spinoff from Novartis (NVS), and says he is incrementally more bullish on the company's revenue and growth drivers.
05/20/19
FBCO
05/20/19
INITIATION
Target $336
FBCO
Neutral
Regeneron initiated with a Neutral at Credit Suisse
Credit Suisse analyst Evan Seigerman started Regeneron Pharmaceuticals (REGN) with a Neutral rating and $336 price target. The analyst is concerned that Eylea could face "increasing headwinds" with the upcoming launch of Novartis' (NVS) brolucizumab. Further, he believes consensus estimates for the Sanofi (SNY) collaboration may be too high.
BHP BHP Group
$52.47

1.18 (2.30%)

05/01/19
SBSH
05/01/19
DOWNGRADE
SBSH
Neutral
BHP Group downgraded to Neutral from Buy at Citi
04/23/19
UBSW
04/23/19
DOWNGRADE
UBSW
Neutral
BHP Group downgraded to Neutral from Buy at UBS
UBS analyst Glyn Lawcock last night downgraded BHP Group to Neutral from Buy with an unchanged price target of 1,900 pence. The stock's rally has been supported by higher iron ore prices, but these should fall over the next six to 12 months, Lawcock tells investors in a research note. The analyst expects prices of both iron and thermal coal to moderate.
05/02/19
SBSH
05/02/19
DOWNGRADE
SBSH
Neutral
BHP Group downgraded to Neutral from Buy at Citi
Citi analyst Heath Jansen downgraded BHP Group to Neutral from Buy and lowered his price target for the shares to 1,900 pence from 1,950 pence. The analyst doesn't see more share upside after Citi reduced its commodities forecast. He believes BHP has reached fair value.
04/22/19
UBSW
04/22/19
DOWNGRADE
UBSW
Neutral
BHP Group downgraded to Neutral from Buy at UBS

TODAY'S FREE FLY STORIES

LGCY

Legacy Reserves

$0.11

-0.0195 (-15.12%)

21:00
06/18/19
06/18
21:00
06/18/19
21:00
Hot Stocks
Legacy Reserves files for Chapter 11 »

Legacy Reserves announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NANO

Nanometrics

$33.56

1.07 (3.29%)

20:33
06/18/19
06/18
20:33
06/18/19
20:33
Initiation
Nanometrics initiated at B. Riley FBR »

Nanometrics initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 10

    Jul

SPY

SPDR S&P 500 ETF Trust

$292.33

2.87 (0.99%)

, SPX

S&P 500

$0.00

(0.00%)

20:26
06/18/19
06/18
20:26
06/18/19
20:26
General news
Breaking General news story on SPDR S&P 500 ETF Trust, S&P 500 »

Trump asked lawyers about…

SPY

SPDR S&P 500 ETF Trust

$292.33

2.87 (0.99%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

20:25
06/18/19
06/18
20:25
06/18/19
20:25
Conference/Events
CLSA Asian tech analysts to hold an analyst/industry conference call »

Asian Technology Analysts…

AMZN

Amazon.com

$1,902.00

16.45 (0.87%)

, FDX

FedEx

$166.32

2.61 (1.59%)

20:02
06/18/19
06/18
20:02
06/18/19
20:02
Periodicals
Amazon.com expanding next-day delivery with more rented jets, WSJ says »

Amazon.com (AMZN) is…

AMZN

Amazon.com

$1,902.00

16.45 (0.87%)

FDX

FedEx

$166.32

2.61 (1.59%)

UPS

UPS

$102.16

0.76 (0.75%)

BA

Boeing

$374.21

19.31 (5.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 09

    Jul

  • 10

    Jul

  • 24

    Jul

  • 30

    Jul

  • 31

    Jul

  • 13

    Nov

DLAKY

Lufthansa

$0.00

(0.00%)

19:53
06/18/19
06/18
19:53
06/18/19
19:53
Downgrade
Lufthansa rating change at Nord/LB »

Lufthansa downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEQU

Kewaunee Scientific

$22.34

0.44 (2.01%)

19:45
06/18/19
06/18
19:45
06/18/19
19:45
Earnings
Kewaunee Scientific reports Q4 EPS (15c) excluding cost items, one estimate 53c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$36.71

0.58 (1.61%)

19:08
06/18/19
06/18
19:08
06/18/19
19:08
Periodicals
GM, UAW negotiating to hire more temps, cut $900M in health cost, Bloomberg says »

General Motors is seeking…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 12

    Aug

FLXS

Flexsteel Industries

$16.77

-0.13 (-0.77%)

19:04
06/18/19
06/18
19:04
06/18/19
19:04
Hot Stocks
Flexsteel Industries updates on restructuring, to incur $48M-$53M charge »

Flexsteel Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$276.80

1.21 (0.44%)

, JBL

Jabil

$27.33

0.53 (1.98%)

19:02
06/18/19
06/18
19:02
06/18/19
19:02
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Adobe…

ADBE

Adobe

$276.80

1.21 (0.44%)

JBL

Jabil

$27.33

0.53 (1.98%)

X

U.S. Steel

$14.58

0.62 (4.44%)

ARQL

ArQule

$9.37

-0.19 (-1.99%)

UPWK

Upwork

$15.15

-0.29 (-1.88%)

MTSI

Macom

$14.40

-0.02 (-0.14%)

LZB

La-Z-Boy

$29.76

-0.47 (-1.55%)

KURA

Kura Oncology

$18.73

-0.76 (-3.90%)

GPRE

Green Plains

$12.48

0.3 (2.46%)

NCR

NCR Corp.

$31.34

0.31 (1.00%)

ZYME

Zymeworks

$20.15

-0.51 (-2.47%)

GNCA

Genocea

$5.16

-0.24 (-4.44%)

YY

YY

$77.13

2.14 (2.85%)

EAF

GrafTech

$10.95

0.14 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 18

    Jun

  • 19

    Jun

  • 19

    Jun

  • 25

    Jun

  • 20

    Jun

PCG

PG&E

$19.15

0.27 (1.43%)

18:59
06/18/19
06/18
18:59
06/18/19
18:59
Periodicals
PG&E to pay $1B to some CA communities to settle wildfire claims, WSJ says »

PG&E has agreed to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

STOK

Stoke Therapeutics

$0.00

(0.00%)

18:46
06/18/19
06/18
18:46
06/18/19
18:46
Syndicate
Stoke Therapeutics 7.89M share IPO priced at $18.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

LTXB

LegacyTexas Financial

$39.02

0.11 (0.28%)

18:36
06/18/19
06/18
18:36
06/18/19
18:36
Downgrade
LegacyTexas Financial rating change at SunTrust »

LegacyTexas Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

UNP

Union Pacific

$165.49

0.885 (0.54%)

18:24
06/18/19
06/18
18:24
06/18/19
18:24
Hot Stocks
Union Pacific CEO: The President is addressing the right topics with China »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

MYOS

MYOS

$1.40

0.11 (8.53%)

18:12
06/18/19
06/18
18:12
06/18/19
18:12
Hot Stocks
MYOS says fortetropin shows increase rate of muscle protein synthesis in study »

MYOS RENS Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$36.71

0.58 (1.61%)

18:06
06/18/19
06/18
18:06
06/18/19
18:06
Periodicals
Breaking Periodicals news story on General Motors »

GM, UAW negotiating to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

  • 12

    Aug

BXC

BlueLinx

$22.03

0.305 (1.40%)

18:00
06/18/19
06/18
18:00
06/18/19
18:00
Hot Stocks
BlueLinx sells two distribution facilities for $12M »

BlueLinx Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EADSY

Airbus

$0.00

(0.00%)

, BA

Boeing

$374.21

19.31 (5.44%)

17:59
06/18/19
06/18
17:59
06/18/19
17:59
Periodicals
U.S. expected to be open to ending aircraft subsidy dispute, Reuters says »

The U.S. is expected to…

EADSY

Airbus

$0.00

(0.00%)

BA

Boeing

$374.21

19.31 (5.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

FB

Facebook

$188.46

-0.43 (-0.23%)

17:56
06/18/19
06/18
17:56
06/18/19
17:56
Periodicals
House Banking chair Waters calls on Facebook to halt Libra, Reuters says »

House Financial Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

OII

Oceaneering

$18.34

0.7 (3.97%)

, APC

Anadarko

$69.95

0.16 (0.23%)

17:36
06/18/19
06/18
17:36
06/18/19
17:36
Hot Stocks
Oceaneering awarded supply contract for Mozambique LNG Project »

Oceaneering (OII)…

OII

Oceaneering

$18.34

0.7 (3.97%)

APC

Anadarko

$69.95

0.16 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

GVA

Granite Construction

$44.64

1.335 (3.08%)

17:35
06/18/19
06/18
17:35
06/18/19
17:35
Hot Stocks
Granite Construction JV awarded $275M highway construction project in Sacremento »

Granite Construction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$69.95

0.16 (0.23%)

, FTI

TechnipFMC

$23.76

0.7 (3.04%)

17:33
06/18/19
06/18
17:33
06/18/19
17:33
Hot Stocks
TechnipFMC awarded subsea contracts by subsidiary of Anadarko Petroleum »

TechnipFMC (FTI) has been…

APC

Anadarko

$69.95

0.16 (0.23%)

FTI

TechnipFMC

$23.76

0.7 (3.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 25

    Jul

MDT

Medtronic

$97.96

0.65 (0.67%)

17:33
06/18/19
06/18
17:33
06/18/19
17:33
Hot Stocks
Medtronic exec Surface sells 9,000 ordinary shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

EAF

GrafTech

$10.95

0.14 (1.30%)

17:20
06/18/19
06/18
17:20
06/18/19
17:20
Syndicate
Breaking Syndicate news story on GrafTech »

GrafTech files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$69.95

0.16 (0.23%)

17:12
06/18/19
06/18
17:12
06/18/19
17:12
Hot Stocks
Anadarko Area 1 Plan of Development now effective »

Anadarko Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.